The Latest Breaking News from Johnson & Johnson (

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 400 points on Tuesday.

Johnson & Johnson (NYSE: JNJ) shares are trading higher Tuesday after the company reported mixed financial results and increased its dividend.

Johnson & Johnson is suspending sales forecasts for its COVID-19 vaccine only a few months after saying the shot could bring in as much as $3.5 billion this year

Johnson & Johnson (NYSE:JNJ) has reported Q1 FY22 adjusted earnings of $2.67 per share, up 3.1% Y/Y and ahead of the consensus of $2.61. Net sales increased 5% Y/Y (7.9% on an operational basis) to $23.43 billion, missing the consensus of $23.67 billion. Pharmaceuticals contributed $12.87 billion in sales, +9.3%, due to Darzalex…

  Johnson & Johnson (NYSE:JNJ) reported its Q1 earnings results on Tuesday, April 19, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

West Virginia will receive $99 million in a settlement finalized with Johnson & Johnson’s subsidiary Janssen Pharmaceuticals Inc. The state filed a lawsuit accusing the drugmaker of contributing to the opioid crisis in the state that's led the nation in overdose deaths

Johnson & Johnson (NYSE:JNJ) is set to give its latest quarterly earnings report on Tuesday, 2022-04-19. Here's what investors need to know before the announcement. Analysts estimate that Johnson & Johnson will report an earnings per share (EPS) of $2.61.

Because concerns over high inflation and increasing sanctions on Russia are expected to fuel stock market volatility in the near term, we think it could be wise to bet on dividend aristocrats Johnson & Johnson (JNJ), Procter & Gamble (PG), PepsiCo (PEP), Abbott (ABT), and Becton Dickinson (BDX) for a…

Despite the rising demand for COVID-19 vaccines and other pharmaceutical products, AstraZeneca (AZN) has failed to deliver impressive earnings in its last quarter. While its recent drug launches are expected to do well in the long run, the consensus earnings estimate for the company in the current quarter indicates tepid…

Rising inflation and the Fed’s signal that it will raise interest rates multiple times this year fostered high market volatility last month. And although the major market indexes rose for the third consecutive trading session yesterday, many analysts expect the market to remain volatile this year. Given this backdrop, we…

Dividend Kings are the crème de la crème of dividend growers and should be top of mind for any investor who puts income stability above all else.